FDA has approved polatuzumab vedotin-piiq (Polivy) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified, or high-grade B-cell lymphoma, and who have an International Prognostic Index score of 2 or greater.
FDA granted priority review to Lonsurf (trifluridine/tipiracil) as monotherapy or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy.
Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus.
mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda (pembrolizumab) was granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.
ArteraAI and the American Cancer Society formed a collaboration focused on the development of AI-driven cancer therapy personalization.
Adaptive Biotechnologies Corporation and Takeda entered into a translational collaboration, utilizing Adaptive’s clonoSEQ Assay to assess minimal residual disease, to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
Caris Life Sciences and Flare Therapeutics formed a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.
University of Florida Health researchers and Nuance Communications Inc., a Burlington, Massachusetts, firm that specializes in radiology voice recognition and AI deployment, formed a research alliance to develop artificial intelligence tools to make radiologists’ work more precise, safe, and efficient.
FDA approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
FDA granted full approval to Keytruda for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
